Company

PhaseBio Pharmaceuticals, Inc.

Headquarters: Malvern, PA, United States

Employees: 60

CEO: Mr. Jonathan P. Mow

NASDAQ: PHAS

Market Cap

$3.5 Million

USD as of Jan. 1, 2023

Market Cap History

PhaseBio Pharmaceuticals, Inc. market capitalization over time

Evolution of PhaseBio Pharmaceuticals, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PhaseBio Pharmaceuticals, Inc.

Detailed Description

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

PhaseBio Pharmaceuticals, Inc. has the following listings and related stock indices.


Stock: NASDAQ: PHAS wb_incandescent

Stock: FSX: 2K4 wb_incandescent

Details

Headquarters:

1 Great Valley Parkway

Suite 30

Malvern, PA 19355

United States

Phone: 610 981 6500

Fax: 610 981 6520